1. Effect of high-dose vitamin D 3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.
- Author
-
Røsjø E, Lossius A, Abdelmagid N, Lindstrøm JC, Kampman MT, Jørgensen L, Sundström P, Olsson T, Steffensen LH, Torkildsen Ø, and Holmøy T
- Subjects
- Adolescent, Adult, Antibodies, Viral blood, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Nuclear Antigens blood, Female, Herpesvirus 4, Human pathogenicity, Humans, Immunoglobulin G blood, Male, Middle Aged, Young Adult, Cholecalciferol therapeutic use, Epstein-Barr Virus Infections drug therapy, Herpesvirus 4, Human drug effects, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Background: Elevated antibody levels against Epstein-Barr virus (EBV) and a poor vitamin D status are environmental factors that may interact in relapsing-remitting multiple sclerosis (RRMS) aetiology., Objectives: To examine effects of high-dose oral vitamin D
3 supplementation on antibody levels against EBV nuclear antigen 1 (EBNA1) in RRMS., Methods: Serum 25-hydroxyvitamin D3 (25(OH)D) and immunoglobulin G antibody levels against EBNA1 (whole protein and amino acid 385-420 fragment), EBV viral capsid antigen (VCA), cytomegalovirus (CMV) and varicella zoster virus (VZV) were measured in 68 RRMS patients enrolled in a 96-week randomised double-blinded placebo-controlled clinical trial of oral vitamin D3 supplementation (20,000 IU/week) (NCT00785473)., Results: The mean 25(OH)D level more than doubled in the vitamin D group and was significantly higher than in the placebo group at study conclusion (123.2 versus 61.8 nmol/L, p < 0.001). Compared to the placebo group, both anti-EBNA1 protein and fragment antibody levels decreased in the vitamin D group from baseline to week 48 ( p = 0.038 and p = 0.004, respectively), but not from baseline to week 96. Vitamin D3 supplementation did not affect antibodies against VCA, CMV or VZV., Conclusion: The results indicate that high-dose oral vitamin D3 supplementation can affect humoral immune responses against the latent EBV antigen EBNA1 in RRMS.- Published
- 2017
- Full Text
- View/download PDF